Table 1 |
||||
|
Efficiency of stable clone generation based on resistance markers and their promoters |
||||
|
Vector |
Resistance marker |
Transcriptional control |
Selective drug (dose) |
Frequency of stable integrants5 |
|
|
||||
|
pPGK-Puro |
Puro |
PGK1 |
Puromycin (0.5 μg/ml) |
>8 × 10-5 |
|
pTracer-BSD |
BSD (GFP fusion) |
EF1α2 |
Blasticidin-S (2.0 μg/ml) |
4.9 × 10-5 |
|
pCMV-BSD |
BSD |
CMV3 |
Blasticidin-S (2.0 μg/ml) |
6.3 × 10-6 |
|
pBM14 |
Neo |
PGK1 |
Geneticin/G418 (50 μg/ml) |
6.0 × 10-6 |
|
pEGFP-C3 |
Neo |
SV404 |
Geneticin/G418 (50 μg/ml) |
6.3 × 10-6 |
|
pRNAT-U6.1 (GFP) |
Hyg |
SV404 |
Hygromycin-B (10 to 100 μg/ml) |
<1.0 × 10-6 (none recovered) |
|
|
||||
|
1Murine phosphoglycerate kinase promoter/enhancer. 2Human elongation factor 1-alpha promoter/enhancer. 3Cytomegalovirus immediate-early promoter/enhancer. 4Simian virus-40 promoter/origin region. 5Values shown represent means of two to six experiments. |
||||
|
Moore et al. Stem Cell Research & Therapy 2010 1:23 doi:10.1186/scrt23 |
||||
